Clinical trial · Observational
Eribulin as a Second-line Treatment in Triple-negative Advanced Breast Cancer
Observational Study Evaluating the Role of Eribulin as a Second-line Treatment in Triple-negative Advanced Breast Cancer
NCT05302778CI-TRIAL-00066705HERMIONE-10unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Multicenter, retrospective and prospective, cohort, observational study evaluating the clinical efficacy and tolerability of Eribulin as second-line treatment in accordance with the indications authorized by AIFA in patients with triple negative advanced breast cancer in a real world setting.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
| Metastatic Breast Cancer | Malignant Breast Neoplasm | CURATED_BROADER | 0.78 |
| Triple Negative Breast Cancer | Triple-Negative Breast Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Progression-free survival (PFS)
- timeFrame
- Entire study duration, approximately 3 years
- description
- PFS defined as time from the beginning of treatment to disease progression or death
Secondary outcomes (7)
- measure
- Time to progression (TTP)
- timeFrame
- Entire study duration, approximately 3 years
- description
- TTP defined as the time from the beginning of treatment to disease progression or death
- measure
- Overall Response Rate (ORR)
- timeFrame
- Entire study duration, approximately 3 years
- description
- OOR defined as the percentage of patients who achieved a partial response (PR) or a complete response (CR) as best response according to RECIST 1.1
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Performance status according to ECOG equal to 0-2 * Locally advanced or triple negative metastatic breast cancer (HR- and HER2-) confirmed histologically * Progressing after first-line chemotherapy for advanced disease * Previous anthracyclines and taxanes therapy (in an adjuvant, neoadjuvant or metastatic), unless the patient is ineligible to receive such treatments * Treatment with Eribulin mesylate since 2017, in accordance with AIFA indications * Adequate haematological, renal and hepatic function, as per clinical practice * Written informed consent Exclusion Criteria: * Breast cancer HER2 + or HR + * Treatment with Eribulin in the context of clinical studies * Patients unsuitable for treatment with Eribulin * Diagnosis of other malignancies in the two years prior to enrollment, with one exception of adequately treated localized basal cell or squamous cell carcinomas of the skin o cervical carcinomas undergoing curative treatment
References
Publications (0)
Data not yet available
No reference posted for this study.